RSS   Newsletter   Contact   Advertise with us

Ohio sues 5 big drug companies over opioid epidemic

Staff Writer | June 1, 2017
Ohio Attorney General Mike DeWine filed a lawsuit against five leading prescription opioid manufacturers and their related companies in Ross County Court of Common Pleas.
Mike DeWine
Medicine   Ohio Consumer Sales Practices Act
The lawsuit alleges that the drug companies engaged in fraudulent marketing regarding the risks and benefits of prescription opioids which fueled Ohio's opioid epidemic.

"We believe the evidence will also show that these companies got thousands and thousands of Ohioans - our friends, our family members, our co-workers, our kids - addicted to opioid pain medications, which has all too often led to use of the cheaper alternatives of heroin and synthetic opioids.

"These drug manufacturers led prescribers to believe that opioids were not addictive, that addiction was an easy thing to overcome, or that addiction could actually be treated by taking even more opioids" said Ohio Attorney General Mike DeWine.

"They knew they were wrong, but they did it anyway - and they continue to do it.

"Despite all evidence to the contrary about the addictive nature of these pain medications, they are doing precious little to take responsibility for their actions and to tell the public the truth."

The five manufacturers which are listed as defendants include

- Purdue Pharma, which sold OxyContin, MS Contin, Dilaudid, Butrans, Hyslingla, and Targiniq

- Endo Health Solutions, which sold Percocet, Percodan, Opana, and Zydone

- Teva Pharmaceutical Industries and its subsidiary Cephalon, which sold Actiq and Fentora

- Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, which sold Duragesic and Nucynta

- Allergan, which sold Kadian, Norco, and several generic opioids.

The lawsuit alleges, among several counts, that the drug companies violated the Ohio Consumer Sales Practices Act and created a public nuisance by disseminating false and misleading statements about the risks and benefits of opioids.

This false marketing included medical journal advertising, sales representative statements, and the use of front groups to deliver information which downplayed the risks and inflated the benefits of certain formulations of opioids.

This behavior proliferated the prescription of opioids and fueled the opioid epidemic Ohio is currently facing.


 

MORE INSIDE POST